TY - JOUR T1 - T-cell and antibody immunity after COVID-19 mRNA vaccines in healthy and immunocompromised subjects-An exploratory study JF - medRxiv DO - 10.1101/2021.05.21.21257442 SP - 2021.05.21.21257442 AU - Rakesh Sindhi AU - Chethan Ashokkumar AU - Brianna Spishock AU - Maggie Saunders AU - Angelo Mabasa AU - Pradeep Sethi AU - Ashok Reddy AU - Bobby Nibhanupudy Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257442.abstract N2 - Background In recent studies, up to half of immunocompromised (IC) subject populations fail to develop antibodies after COVID-19 vaccination.Purpose and Methods Here, we explore whether T-cells which respond to the spike (S) antigenic sequence and its less conserved S1, and the conserved S2 component are present in serial samples before and after each dose of mRNA1273 or BNT162b2 vaccines in 20 healthy immunocompetent subjects. Single samples from 7 vaccinated IC subjects were also tested. Simultaneously, we measured IgG antibodies to the receptor binding domain (RBD) of S1, and anti-S IgG, and frequencies of monocytic CD14+HLA-DR-(M-MDSC) and polymorphonuclear CD14-CD15+CD11b+ (PMN-MDSC) myeloid-derived suppressor cells.Results In healthy subjects, S1-, S2-, and S-reactive CD4 and CD8 T-cell frequencies showed a numeric but not statistically significant decrease after the first vaccine dose and were accompanied by increased MDSC frequencies (p<0.05). After the second dose, S2-and S-reactive CD4 and CD8 cells and MDSC approached pre-vaccination levels. In healthy subjects, a) S1-reactive CD8 frequencies were significantly higher after the second dose compared with pre-vaccination levels (p=0.015), b) anti-RBD and anti-S IgG were present in all after the second dose. Among seven IC subjects, anti-RBD and anti-S IgG were absent in 4 and 3 subjects, respectively. S1-reactive CD8 cells were identified in 2 of 4 anti-RBD negative subjects. S-reactive CD4 or CD8 cells were identified in all three anti-S negative subjects.Conclusions In healthy immunocompetent subjects, mRNA vaccines induce antibodies to the spike antigenic sequences and augment CD8 cells reactive to the S1 spike sequence, which is more specific for the SARS-CoV-2 virus. In this exploratory cohort of vaccinated immunocompromised subjects, S1-reactive CD8 cells can be detected in some who are negative for RBD antibody, and S-reactive T-cells are present in all who are negative for spike antibody.Competing Interest StatementUniversity of Pittsburgh Patent 9606019, author: RS, describes CMI testing for CMV, is licensed exclusively to Plexision, in which University and RS own equity. RS and CA developed Plexision s patent-pending multi-variate CMI assay for SARS2. RS is Professor of Surgery at the University of Pittsburgh and Chief Scientific Officer of Plexision by permission of COI committee at the University. CA is a paid consultant to Plexision. Other authors have nothing to disclose.Funding StatementNSF#2033307-PI CA, intramural support from Plexision.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were reviewed and approved by Advarra Institutional Review Board (IRB), Columbia, MD. Subjects were enrolled under IRB-approved protocols Pro00045352 and Pro00053511 (Advarra IRB, Columbia, MD) (NCT#04883164). Informed consents were obtained from all participants in the studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data that underlie the results reported in this Article (including study protocol) on individual participants will be made available to researchers who provide a methodologically sound proposal to the corresponding author. ER -